# Mérieux Equity Partners

> Mérieux Equity Partners is a VC fund backing Health Care and Biotechnology. See 57 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Lyon, France
- Total investments: 57
- Last investment: Apr 2025
- Lead investor: 37%
- Fund size: $417M
- Last fund: Jan 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/676539/admin/updates/
- Website: https://www.merieux-partners.com

Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.

## Contacts

5 contacts available for Mérieux Equity Partners. Shizune tracks 6 team members at Mérieux Equity Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/merieux-equity-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.7M–$23M |
| Private Equity | $22M–$150M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 29 | 51% |
| Biotechnology | 23 | 40% |
| Medical Device | 13 | 23% |
| Medical | 12 | 21% |
| Manufacturing | 11 | 19% |

36 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 18% |
| Private Equity | 10 | 18% |
| Funding Round | 9 | 16% |
| Series B | 8 | 14% |
| Series C | 8 | 14% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 18 | 32% |
| United States | 11 | 19% |
| Belgium | 3 | 5% |
| Switzerland | 2 | 4% |
| United Kingdom | 2 | 4% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Francois Valencony | Managing Partner,/founder & Executive Officer; Managing Partner & Executive Officer | 16 | https://shizune.co/investors/profile/francois-valencony |
| Jean-Francois Billet | Senior Partner | 2 | https://shizune.co/investors/profile/jean-francois-billet |
| Jean-Guillaume Lafay | Operating Partner | 0 | https://shizune.co/investors/profile/jean-guillaume-lafay |
| Thierry Chignon | Senior Partner | 4 | https://shizune.co/investors/profile/thierry-chignon-2 |
| Valerie Calenda | Managing Partner | 16 | https://shizune.co/investors/profile/valerie-calenda |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DeepUll | DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M | Series C | Apr 29, 2025 |  |
| Ceva Santé Animale | Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs. |  | Private Equity | Mar 31, 2025 |  |
| CorFlow Therapeutics | CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $48.5M | Series B | Sep 10, 2024 |  |
| Prothea Technologies | Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit. | $13M | Series A | Apr 09, 2024 |  |
| Amyl Therapeutics | Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. | $5.7M | Series A | Nov 07, 2023 |  |
| Broken String Biosciences | Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies. | $15M | Series A | Sep 18, 2023 |  |
| TISSIUM | TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | $53.8M | Series D | May 23, 2023 |  |
| Mablink Bioscience | Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC). | $30.1M | Series A | Oct 14, 2022 |  |
| AstriVax | AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. | $29.9M | Seed | Aug 25, 2022 |  |
| Cairdac | Cairdac is a manufacturer of autonomous leadless pacing transcatheter system capable of powering the device with no battery-life limitation. | $18.8M | Series A | Mar 31, 2022 |  |

10 of 57 investments shown.

## Co-investors
- [Mérieux Equity Partners](https://shizune.co/investors/profile/m%C3%A9rieux-equity-partners) — VC Fund, 38 deals together
- [NanoDimension](https://shizune.co/investors/profile/nanodimension) — VC Fund, 5 deals together
- [+ND Capital](https://shizune.co/investors/profile/nd-capital) — VC Fund, 5 deals together
- [Paladin Capital Group](https://shizune.co/investors/profile/paladin-capital-group) — VC Fund, 5 deals together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 4 deals together
- [Shire](https://shizune.co/investors/profile/shire) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Health Care Investors in France](https://shizune.co/investors/health-care-investors-france)
- [Health Care VC Funds in France](https://shizune.co/investors/health-care-vc-funds-france)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)

## FAQ

### What does Mérieux Equity Partners invest in?

Mérieux Equity Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Private Equity stage. Most of the 57 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Mérieux Equity Partners's check size?

Mérieux Equity Partners typically joins rounds of $5.7M–$23M at Series A and $22M–$150M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mérieux Equity Partners participates in.

### How do I contact Mérieux Equity Partners?

Public channels for Mérieux Equity Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Mérieux Equity Partners?

The team at Mérieux Equity Partners includes Francois Valencony (Managing Partner,/founder & Executive Officer; Managing Partner & Executive Officer), Jean-Francois Billet (Senior Partner) and Jean-Guillaume Lafay (Operating Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co